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http://dx.doi.org/10.1016/j.ccell.2014.11.017SUMMARYBreast cancer bone micrometastases can remain asymptomatic for years before progressing into overt
lesions. The biology of this process, including the microenvironment niche and supporting pathways, is
unclear. We find that bone micrometastases predominantly reside in a niche that exhibits features of osteo-
genesis. Niche interactions are mediated by heterotypic adherens junctions (hAJs) involving cancer-derived
E-cadherin and osteogenic N-cadherin, the disruption of which abolishes niche-conferred advantages. We
elucidate that hAJ activates themTOR pathway in cancer cells, which drives the progression from single cells
to micrometastases. Human data set analyses support the roles of AJ and the mTOR pathway in bone colo-
nization. Our study illuminates the initiation of bone colonization, and provides potential therapeutic targets
to block progression toward osteolytic metastases.INTRODUCTION
When diagnosed in the clinic, breast cancer bone metastases
are primarily osteolytic and driven by a vicious cycle betweenSignificance
In advanced stages, breast cancer bonemetastases are driven
osteoclasts, which constitute a vicious osteolytic cycle. Curre
but do not improve patient survival. On the other hand, bon
activating the vicious cycle, providing a therapeutic opportun
colonization is initiated in a microenvironment niche exhibiting
erotypic adherens junctions, which enhance mTOR activity a
These results reveal a strong connection between osteogenesi
gets to prevent bone macrometastases.
Ccancer cells and osteoclasts (Ell and Kang, 2012; Kozlow and
Guise, 2005; Mackiewicz-Wysocka et al., 2012; Mundy, 2002;
Weilbaecher et al., 2011). Bisphosphonates (Diel et al., 1998)
and denosumab (Lipton et al., 2007) have been used to inhibitby paracrine crosstalk among cancer cells, osteoblasts, and
nt therapies targeting this process limit tumor progression,
e micrometastases may remain indolent for years before
ity to prevent macrometastases. Here, we show that bone
active osteogenesis. Cancer and osteogenic cells form het-
nd drive early-stage bone colonization prior to osteolysis.
s andmicrometastasis and suggest potential therapeutic tar-
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this vicious cycle and achieved a significant delay of metastasis
progression, but they have not improved patient survival (Cole-
man et al., 2008; Mackiewicz-Wysocka et al., 2012; Onishi
et al., 2010). Recent studies have elucidated roles for various
pathways in osteolytic bone metastasis, including TGF-b, hyp-
oxia, Hedgehog, Integrin, and Notch (Bakewell et al., 2003; Buijs
et al., 2011; Dunn et al., 2009; Heller et al., 2012; Kang et al.,
2003; Sethi et al., 2011). Molecular and cellular events that
initiate the vicious cycle have also been identified. Specifically,
cancer-cell-derived and expressed VCAM-1 has been shown
to engage osteoclast progenitor cells and accelerate their differ-
entiation, which may represent a critical step for microscopic
bone metastases to progress into clinically significant lesions
(Lu et al., 2011). These findings provide further therapeutic tar-
gets to intervene in the osteolytic cycle.
In contrast to our knowledge of overt bone metastases, we
know much less about microscopic bone metastases prior to
the osteolytic cycle. In fact, such micrometastases may remain
asymptomatic for a prolonged period of time before being reac-
tivated to progress, a clinical phenomenon often referred to as
metastasis dormancy (Aguirre-Ghiso, 2007). Disseminated
tumor cells (DTCs) in the bone marrow have been detected in
patients that appear tumor free (Pantel et al., 2008, 2009).
DTCs may establish their first foothold in the bone marrow by
competing with hematopoietic stem cells for the niche occu-
pancy (Shiozawa et al., 2011). However, it remains elusive how
cancer cells interact with the niche cells to begin colonization
and whether there are intermediate stages between solitary
DTCs and osteolytic metastases.
RESULTS
Intrailiac Artery Injection of Breast Cancer Cells
Enriches for Microscopic Bone Lesions, Allowing
Inspection of Preosteolytic Bone Colonization
We used intrailiac artery (IIA) injection to monitor early-stage
bone colonization. This approach selectively delivers cancer
cells to hind limb tissues and bone through the external iliac
artery (Figure 1A) without damaging local tissues. We character-
ized this approach and compared it to intracardiac (IC) injection,Figure 1. IIA Injection to Introduce and Model Indolent Bone Lesions
(A) Diagram illustrates IIA injection. Red and blue lines indicate arteries and vein
(B) Fluorescence imaging shows RFP-labeled MDA-MB-231 cells in bone 4 hr aft
Scale, 100 mm.
(C) MDA-MB-231 bone colonization kinetics after IIA injection. (Top) Bone colon
(Bottom) Representative BL images at indicated time points. Error bars, 95% co
(D) TRAP staining of the osteolytic bone lesions or counterlateral tumor-free con
(E) Representative BL images showing the organ distribution of MDA-MB-231 ce
(F) Quantification of BL signals from hind limb bones, lungs, and brain, respective
5 3 105 cells (IIA-5 3 105), or IC injection of 1 3 105 cells (IC-1 3 105). (Bottom)
Error bars, SD.
(G) Bone colonization of admixed MDA-MB-231 parental cells (Par, RFP+) and a b
IIA injection.
(H) Same as (C) except that 2 3 105 MCF-7 cells were examined. Error bars, 95%
(I) IF costaining of Keratin 8 (K8, red) and H2B-GFP (green) (a) and (b) or Ki67 (green
(J) TRAP staining of normal bone or MCF-7 osteolytic bone lesions after IIA injectio
postosteolytic (e), and day 90 (f).
(K) Quantification of the TRAP staining of different time points after IIA injection. *
and day 90 (p = 0.002) than that of tumor-free control. On day 90, the bone lesio
Scale bar, 25 mm, except (B). See also Figure S1.
Ca widely used technique in bone metastasis research. Specif-
ically, we examined the following: (1) the course of metastatic
colonization, (2) organ distribution of disseminated tumor cells,
and (3) the potential Darwinian selection process. Cell lines of
different subtypes were analyzed to reveal the diverse metasta-
tic behaviors of breast cancer cells.
MDA-MB-231 cells (ER/PR/Her2) are known to metasta-
size aggressively in xenograft models. Single cancer cells were
readily detectable in the bonemarrow immediately after IIA injec-
tion (Figure 1B). Strong bone lesions developed within 40 days,
as indicated by the bioluminescence (BL) signals (Figure 1C).
We stained the bone lesions for tartrate-resistant acid phospha-
tase (TRAP), a hallmark of activated osteoclasts, to ask if the
lesions would progress fully. Positive staining was markedly
increased compared to tumor-free counter-lateral legs of the
same animals, indicating ongoing osteolytic cycle (Figure 1D).
Compared to IC injection, cancer cells injected via IIA are pre-
dominantly localized to the hind limb bones, sparing lungs, the
brain, and other soft tissue organs excessive tumor burdens (Fig-
ures 1E and 1F). A larger quantity of cancer cells (e.g., 5 3 105
MDA-MB-231 cells) can be injected through IIA without causing
thrombosis-related deaths to animals (Figure 1F), a phenome-
non often seen during IC injection. As a result of the highly
targeted delivery of cancer cells, full body BL signals strongly
correlated with those from dissected bones (Figure S1A avail-
able online). We then designed a clonal competition assay to
ask if IIA-injected cancer cells encounter a Darwinian selection
process. We admixed RFP-tagged parental MDA-MB-231 cells
with a GFP-tagged bone-tropic clone MDA-MB-231 SCP28
(Minn et al., 2005) at a 1:1 ratio. In 2 weeks, the GFP+/RFP+
shifted dramatically from 1:1 to >10:1 (Figures 1G and S1B) in
both IIA and IC models, reflecting the Darwinian selection pro-
cess during bone colonization.
We then examined MCF-7 cells (ER+/PR+/Her2), a cell line
experimentally more indolent than MDA-MB-231 cells. IIA injec-
tion delivered MCF-7 cells primarily to the hind limb. IC injection
only resulted in detectable bone colonization in two of five mice,
whereas IIA injection gave rise to bone lesions in all five animals
examined (Figures S1C and S1D). The kinetics of MCF-7 bone
colonization was slow in the first 2–4 weeks, but accelerateds, respectively.
er IIA injection. Blue, DAPI; red, RFP; EP, epiphyseal plate; BM, bone marrow.
ization growth curves of a representative experiment of 1 3 105 cells injected.
nfidence interval (CI).
trol of MDA-MB-231 IIA model.
lls introduced via IIA versus IC injection.
ly, in animals receiving IIA injection of 13 105 cells (IIA-13 105), IIA injection of
Ex vivo BL imaging. The p values were computed between IIA and IC models.
one-tropic single-cell population (Bo-SCP, GFP+) at indicated time points after
CI.
) (c) on twoMCF-7 bone lesions on day 14; (b) and (c) are consecutive sections.
n. Tumor-free control (a), day 14 (b), day 28 (c), day 35 preosteolytic (d), day 35
TRAP staining coverage was significantly higher in lesions on day 35 (p = 0.01)
ns occupied almost all metaphysis area. Error bars, SD.
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afterward (Figure 1H). We used an inducible H2B-GFP system to
track the proliferation history of individual cells (Figure S1E;
Fuchs and Horsley, 2011). Although some cancer cells pro-
gressed to microscopic lesions in 2 weeks, a proportion stayed
positive for H2B-GFP (Figure 1I). Ki67 staining on consecutive
sections confirmed that these H2B-GFP+ cells were not prolif-
erative (Figure 1I). Therefore, the fates of cancer cells vary
after their arrival in the bone marrow. There was no
enrichment of TRAP staining in or surrounding tumor
lesions on day 28 or earlier (Figure 1J). Starting on day 35,
some lesions showed increased TRAP staining, indicating a
transition toward the osteolytic cycle (Figures 1J and 1K). We
used this information to define a preosteolytic stage. The pre-
osteolytic phase can be much longer in other models, such
as MDA-MB-361 cells (ER+/PR+/Her2+), which did not exhibit
increased TRAP signals until 4 months after IIA injection (Fig-
ures S1F and S1G) in a minority of mice (2 of 10). Taken
together, these data show that IIA injection is useful to investi-
gate the early stage of bone colonization prior to the osteolytic
cycle.
The Microenvironment Niche of Microscopic Bone
Lesions Is Primarily Comprised of ALP+ and Col-I+ Cells
To ask if bone colonization initiation requires interactions with
specific bone cells, we performed IIA injection of MCF-7 cells
and MDA-MB-361 cells. We also examined 4T1 and 4TO7
cells into syngeneic BALB/c mice to include the competent
immune system. In the preosteolytic stage, we conducted
immunofluorescence (IF) staining of various cell type markers
in conjunction with GFP (for MCF-7, 4T1, and 4TO7 cells) or
Keratin 8 (for MDA-MB-361). We found that the niche cells
express abundant alkaline phosphatase (ALP) and collagen-I
(Col-I), markers of the osteoblast lineage (Figure 2A). In
contrast, only a minority of lesions directly contacted CTSK+
osteoclasts (Figure 2A), and there were mostly fewer CTSK+
cells surrounding the microscopic lesions, confirming the pre-
osteolytic status.
We then quantitated niche composition. The niche was
defined as the single layer of cells that directly contact bone
lesions. We quantitated the following: (1) the frequency of
each cell type relative to other cell types, and (2) the frequency
of niches containing each cell type. First, ALP+ cells accounted
for about 80% of niche cells, Col-I+ cells accounted for 40%–Figure 2. TheMicroenvironment Niche of Microscopic Lesions Is Prima
Osteogenesis
(A) IF costaining of cancer cells (green) and ALP (a–d), Col-I (e–h), or CTSK (i–l). C
parentheses.
(B) Quantification of indicated cell types in the osteogenic niche. The y axis is the p
(first four series) or in the tumor-free metaphysis area (the last series).
(C) Same as (B) except that the absolute numbers of indicated cell types are qua
(D) Percentage of microscopic bone lesions that have in their niche at least two
(E–G) IF staining of RUNX2 (E), Osterix (F), and Sox9 (G) in the vicinity ofMCF-7 lesi
microenvironment niche is shown in the corresponding figure in the form of perc
(H) IF staining MCF-7 cells (green) and b-catenin (red) on bone lesions is shown.
indicate the membrane localization of this protein.
(I) Representative picture of toluidine blue staining and bone histomorphometry
osteoid. Scale, 50 mm.
(J) Quantification (n = 3 mice) of osteoid (left) and osteoclast (right) coverage bas
Error bars, SD. Scale bar, 25 mm, except (I). See also Figure S2.
C65%, and CTSK+ cells accounted for less than 20% (Figure 2B).
The frequencies of ALP+ and Col-I+ cells were 10% and 3% in
the tumor-free metaphysis area, suggesting enrichment of
these cells in the niche. The absolute numbers of each cell
type also were counted (Figure 2C), leading to the same conclu-
sion. Second, we assessed the proportion of lesions that had at
least two cells of each type in the niche (Figure 2D). All niches
contained ALP+ and Col-I+ cells, strongly suggesting that these
cells are associated with the progression to multicell lesions.
CTSK+ cells were only found in a minority of niches in MCF-7,
MDA-MB-361, and 4T1 models. In the 4TO7 model, CTSK+
cells were found in all niches examined with a relatively low fre-
quency in each niche (Figures 2B and 2C). We also examined
cells expressing Nestin, CD31, aSMA, and CD45 (Figure S2A).
None of these cell types were nearly as frequent as ALP+ and
Col-I+ cells.
Taken together, these findings suggest that ALP+ and Col-I+
cells are the primary components of the microenvironment niche
in early stage bone colonization. In contrast, the abundance of
CTSK+ osteoclasts and other cell types in the niche is relatively
minor.
The Microenvironment Niche of Microscopic Bone
Lesions Exhibits Features of Osteogenesis
ALP and Col-I are associated with osteogenesis, or bone forma-
tion, and have been used as cell markers of osteoblasts (Lynch
et al., 1995; Pittenger et al., 1999). Several lines of evidence indi-
cate that the niche of the microscopic lesions involves an active
osteogenesis process. First, a variable proportion of the niche
cells expressed RUNX2 and Osterix (Osx) (Figures 2E, 2F, and
S2B), master regulators of osteogenesis. In contrast, the chon-
drogenesis regulator SOX9 was not detected in the niche (Fig-
ure 2G). Second, the niche cells displayed active canonical
WNT signaling, as indicated by the nuclear localization of b-cat-
enin (Figure 2H, openarrows) andLEF-1 expression (Figure S2C).
WNT signaling is a major driving force of osteogenesis (Baron
and Kneissel, 2013; Long, 2012). Of note, b-catenin was also
observed along the membrane, suggesting adherens junctions
(AJs) (Figure 2H, solid arrows). Third, histomorphometry ana-
lyses showed a 3- to 5-fold higher osteoid (newly formed
osteoblasts) coverage in areas directly adjacent to the lesions
(Figures 2I and 2J). In contrast, the osteoclast coverage was
not affected (Figures 2J and S2D). Collectively, these findingsrily Comprised of Cells of the Osteoblast Lineage and Exhibits Active
ancer cell lines are indicated to the left of images. Time points are indicated in
ercentage of indicated cell types that directly contact bonemicroscopic lesions
ntified.
cells of the indicated type directly contacting cancer cells.
ons (green) is shown. The frequency of the cells expressing thesemarkers in the
ent ± SD.
Open arrows point to b-catenin staining localized to nucleus, and solid arrows
analysis. Red dotted lines enclose bone lesions and blue dotted lines indicate
ed on histomorphometry analyses shown in (I) and Figure S2D, respectively.
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Figure 3. Osteogenic Cells Directly Contact Cancer Cells to Confer Proliferative Advantages and Accelerate Bone Colonization
(A) Fluorescence imaging of the mammosphere or heterotypic organoid structures in 3D cultures (day 3). Cell names are indicated in respective fluorescence
colors (a–h). The admixture of the same MCF-7 cells tagged with two different colors (g). hMSC, human MSCs; mMSCs, mouse (BALB/c) MSCs; RAW264.7-D,
differentiated mouse osteoclasts derived from RAW264.7 cells; hFOB1.19, human osteoblast cell line. Scale, 50 mm.
(B) Quantification of growth advantages conferred by different cells 3D cultures as a function of time. U937, human monocytes; U937-D, differentiated human
monocytes (osteoclasts); RAW264.7, mouse monocytes; RAW264.7-D, differentiated RAW264.7 cells (osteoclast). The data were then normalized to the values
of control group for each well (n = 3–5).
(legend continued on next page)
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strongly support that the osteogenesis process is associated
with the niche of microscopic lesions. Therefore, we will use
the term osteogenic niche to describe the microenvironment of
early-stage bone colonization.
Cells at Different Stages ofOsteogenesis, orOsteogenic
Cells, Promote Cancer Cell Proliferation in a Cell-Cell
Contact-Dependent Manner
To model the interaction with niche cells, we performed cocul-
ture assays using bone cells representing different stages of
osteogenesis. Specifically, we used an immortalized human
MSC cell line (Liu et al., 2011) and primary murine MSCs of
BALB/c mice. We also used MC3T3 cells and FOB1.19 cells to
represent more differentiated osteoblast precursor cells and
osteoblasts, respectively. The osteogenesis capacity of some
of these cells was validated in vitro (Figure S3A). To ask if cells
from other lineages would have similar effects, we chose U937
and RAW264.7, two monocyte lines that can differentiate into
osteoclasts.
In 2D cultures, MSCs promoted cancer cell growth in a dose-
dependent manner (Figure S3B). When the two cell types were
separated using Boyden Chamber, the promoting effects were
diminished (Figure S3C), suggesting the necessity of direct
cell-cell contact. We next performed cocultures in 3D suspen-
sion conditions widely used in mammosphere assays. Interest-
ingly, cancer cells and osteogenic cells formed a heterotypic
organoid structure with an oncogenic shell and an osteogenic
core (Figure 3A). This structure was not observed with
the same cancer cells labeled with another color or with
RAW264.7 cells (Figure 3A). Compared to the osteogenic niche
structure in vivo (Figure 2A), the relative positioning (or polarity)
of cancer and osteogenic cells was inverted in the heterotypic
organoids. However, the organoids did recapitulate the exten-
sive and direct contact between two cell types. Both MSC
and FOB1.19 cells were able to accelerate tumor cell prolifera-
tion, with the effects increasing over time (Figure 3B). The
effects of the monocytes were modest (Figure 3B), even after
they differentiated into osteoclasts. Cancer cells in the hetero-
typic organoids exhibited a large increase of Ki67 staining,
whereas the osteogenic cells in this structure appeared to differ-
entiate with increased ALP expression (Figure 3C). The effects
of MSCs on MCF-7 cells can be reproduced in a number of
other cancer cell models as well as using more differentiated
osteogenic cells (Figure 3D).(C) (Top) IF staining of Ki67 on MCF-7 mammospheres and heterotypic organoid
types. (Bottom) IF staining of GFP (green) and ALP (red) on MSC-spheres (GFP-
labeled MSCs). Scale bar, 25 mm.
(D) Quantification of firefly luciferase-labeled cancer cells (as indicated below th
(indicated by white/blue boxes) in 3D cultures. The BL signal intensity wasmeasur
normalized to the values of control group for each well (n = 3–5).
(E) IF costaining of RFP (MCF-7 cells) and GFP (hMSCs) within 4 hr after IIA injec
(F) Representative in vivo and ex vivo BL images showing the bone colonization pr
amounts of MSCs were injected.
(G) (Left) BL signal intensity as a function of time after IIA injection of MCF-7 cells, w
respectively). Error bars, 95% CI. (Right) Quantification of ex vivo BL signals at the
log transformation.
(H) Same as (G) except that 5 3 105 MDA-MB-361 cells were used for IIA injecti
(I) Same as (G) except that 5 3 103 4TO7 cells and mouse (BALB/c) MSCs were
Error bars, SD unless otherwise noted. See also Figure S3.
CProvision of Exogenous MSCs Promotes Bone
Colonization In Vivo
To ask if osteogenic cells promote cancer cell proliferation in the
bone microenvironment, we performed IIA injection using
admixed cancer cells and osteogenic cells at a 1:1 ratio. Upon
arrival at the bone marrow, about 50% of MCF-7 cells paired
withMSCs via direct cell-cell contact (Figure 3E). The exogenous
MSCs significantly decreased the latency and increased the
tumor burden of bone colonization (Figures 3F and 3G). Similar
results were also obtained using MDA-MB-361 cells (Figures
3H and S3D) and 4TO7 cells (Figure 3I). For the latter, the coin-
jection was performed on immunocompetent BALB/c mice.
Cancer Cells and Osteogenic Cells Form hAJs Using
E-cad and N-cad
The direct and tight contact between microscopic lesions and
the osteogenic niche led us to hypothesize that they form cell-
cell junctions. The cancer cells used in previous experiments
expressed variable levels of E-cadherin (E-cad) (Figure S4A).
Interestingly, E-cad in cancer cells appears to be required for
effects of osteogenic cells, as cancer cell lines without E-cad
could not gain proliferative advantages from cocultured MSCs
(Figure S4B). On the other hand, the osteogenic cells primarily
expressed N-cadherin (N-cad) and OB-cadherin (OB-cad), but
not E-cad. Since N-cad and E-cad have been reported to form
heterotypic adherens junctions (E-N hAJs) in vitro (Straub
et al., 2011), we first focused on the interaction between these
two cadherins. Several lines of evidence support the formation
of E-N hAJs. First, costaining of E-cad and N-cad in heterotypic
organoids confirmed that they are exclusively expressed in can-
cer cells and osteogenic cells, respectively, and are colocalized
to the border of the two cell types (Figure 4A, arrows), where
b-catenin is also localized (Figure 4B). Likewise, in the bone
lesions, E-cad, N-cad, and b-catenin were aligned to the
cancer-niche interface as well (Figures 4C and 2H). Second, a
biochemical assay showed that E-cad was coimmunoprecipi-
ated with N-cad, indicating that they physically interact with
each other in vitro (Figure S4C). Third, a proximity ligation assay
(PLA), which reflects molecular interaction in situ (So¨derberg
et al., 2006), showed that E-cad and N-cad are colocalized
in vitro and in microscopic bone lesions in vivo (Figures 4D and
S4D). Costaining of N-cad and other markers revealed that
N-cad is mainly expressed by ALP+ cells, but not CTSK+ cells,
both in the niche of microscopic lesions (Figure 4E) and in thes (MCF-7 + hMSCs). The dotted line indicates the border between the two cell
labeled MSCs alone) and the heterotypic organoids (unlabeled MCF-7 + GFP-
e x axes) with or without coculturing with equal numbers of osteogenic cells
ed on day 3 to reflect the alteration of cancer cell quantities. The data were then
tion. Arrows indicate colocalization of the two cell types. Scale, 100 mm.
ocesses at the indicated time points. MCF-7 cells (23 105) with or without equal
ith or without coinjection of humanMSCs (n = 7, 13 for mono- and coinjection,
terminal time point. The intensity is normalized to the day 0 values followed by
on.
used for IIA injection.
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normal bone (Figure S4E). We also asked if endothelial cells are
another major source of N-cad. However, endothelial cells only
accounted for a minority of cells in the niche (Figure S2A) and
only a small proportion of N-cad was colocalized with the
endothelial cell marker, CD31 (Figure S4E). Taken together,
these data strongly support that the E-N hAJ mediates the
interaction between cancer cells and osteogenic cells in vitro
and in vivo.
Evidence Supporting the Role of E-N hAJs in Clinical
Specimens
In the clinic, bonemetastases most frequently occur in tumors of
the luminal subtype, which are typically ER+ (Kennecke et al.,
2010; Smid et al., 2008). E-cad is the major cadherin in this sub-
type (Figure S4F; Perou et al., 2000; Sørlie et al., 2001). Our data
suggest that E-cad in cancer cells mediates tumor-niche interac-
tion, and might provide an explanation for the bone-tropism of
luminal breast cancer. Expression of E-cad is weakly but signif-
icantly associated with worse overall survival and distant metas-
tasis-free survival in the METABRIC (Curtis et al., 2012) and
Erasmus data sets (Smid et al., 2008), respectively (Figure S4G).
A further analysis revealed that E-cad is associated with bone
metastasis specifically in the luminal subtype, which expresses
a high level of E-cad (Figures 4F and S4F), but not in the basal
subtype (Figures S4F and S4H). These results support the hy-
pothesis that E-cad may mediate bone colonization if expressed
in cancer cells, being the seeds of metastasis.
On the other hand, the soil of bone metastasis, namely the
bone and bone marrow, is largely E-cad low or negative (Figures
4C and S4I). The osteogenic cells includingMSCs highly express
N-cad and OB-cad (Figure S4A). Thus, if AJs are required for
cancer cells to colonize the bone, they are likely to be constituted
by E-cad of cancer cells and N-cad or OB-cad of osteogenic
cells.
The cadherin expression of human bone metastases retains
the features of normal bone, in that N-cad and OB-cad are ex-
pressed at a higher level than metastases in other organs (Fig-
ure 4G). This suggests that metastatic bone lesions are heavily
infiltrated by osteogenic cells. E-cad is expressed at a slightly
lower level (Figure 4G), which is counterintuitive because cancer
cells in bone metastases are mostly ER+ and expected to ex-Figure 4. The hAJs Are Comprised of E-cad of the Cancer Cells and N
(A) IF costaining of E-cad and N-cad on heterotypic organoids between MCF-7 c
three channels (blue, DAPI; green, N-cad; red, E-cad). Arrows indicate close pro
(B) IF staining of b-catenin (red) on heterotypic organoids between MCF-7 cells
border between the two cell types.
(C) IF costaining of E-cad and N-cad on bone lesions of different sizes. Signals a
indicate close proximity or overlap between E-cad and N-cad signals.
(D) PLAs showing the interaction between E-cad and N-cad. (Left) PLAs perform
lesions in vivo. (Top Left) A negative control experiment using antibodies against
E-cad antibodies. Purple dots indicate successful reactions. (Top Right) GFP sta
using N-cad and E-cad antibodies. Dashed lines indicate the border of cancer c
(E) IF staining of N-cad (green) and ALP or CTSK onmicroscopic bone lesions. MC
three channels are shown on the right (blue, DAPI; green, N-cad; red, ALP (top)
(F) Kaplan-Meier plot of the probability of cumulative bone metastasis-free surviva
to the expression of E-cad (CDH1). The numbers of bone metastases and total pa
(G and H) Box-whisker plots show the relative expression of indicated genes in br
on each box indicate individual specimen. Sample sizes are shown in parenth
combined.
Scale bar, 25 mm. See also Figure S4.
Cpress E-cad (75% of bone metastases versus 47% of other
metastases are ER+). A plausible explanation is that the infil-
trated mesenchymal cells, rich in N-cad and OB-cad but scarce
in E-cad, may dilute the overall level of E-cad of the entire lesion.
Indeed, at the transcriptomic level, bone metastases exhibit
mesenchymal characteristics, as reported in previous studies
(Zhang et al., 2013).
Bone metastases also differ from other metastases in their
enhanced expression of constitutive AJ components including
a-catenin, b-catenin, and p120-catenin, suggesting the preva-
lence of AJ machinery (Figure 4H). Taken together, these data
support the importance of AJs in human bone metastases.
The hAJs Mediate the Cancer-Promoting Effects of the
Osteogenic Niche
We used EGTA to titrate Ca2+ and disrupt AJs. At 1 mM, EGTA
significantly decreased cancer cell proliferation in the hetero-
typic organoids, but had little effect on mammospheres formed
by only cancer cells, suggesting a selectively more stringent
dependence on Ca2+ of hAJs (Figure 5A). Antagonizing E-cad
by a neutralizing antibody (anti-Ecad) or by inducible expression
of dominant negative E-cad (DN-Ecad) (Nieman et al., 1999) both
led to decreased cancer cell proliferation in the heterotypic orga-
noids (Figures 5B, 5C, and S5A). We next perturbed N-cad in
osteogenic cells by a neutralizing antibody (anti-Ncad) and
siRNAs (si-Ncads). Both treatments resulted in decreased ability
of osteogenic cells to promote tumor proliferation (Figures 5D,
5E, and S5B). In contrast, siRNAs against OB-cad did not have
the same effect (Figure S5C). Finally, N-cad-coated plates
conferred a stronger growth advantage to E-cad-expressing
cancer cells compared to other recombinant cadherins (Figures
5F and S5D). Collectively, these results strongly argue that hAJs
are required for the osteogenic-cell-conferred proliferative
effects on cancer cells in vitro.
To test the importance of AJs in vivo, we administered anti-
Ecad on animals receiving MCF-7 cells through IIA. This treat-
ment significantly delayed early bone colonization (Figures 5G
and 5H), and resulted in microscopic lesions that appeared
smaller and less proliferative (Figure 5I). Inducible expression
of DN-Ecad achieved similar effects (Figures 5J–5L). The effects
of DN-Ecad appeared to be specific to bone metastasis, as the-cad of the Osteogenic Cells
ells and MSCs (top) or osteoblasts (bottom) is shown. Signals are merged from
ximity or overlap between E-cad and N-cad signals.
and MSCs (top) or osteoblasts (bottom). The green dashed line indicates the
re merged from three channels (blue, DAPI; green, N-cad; red, E-cad). Arrows
ed on heterotypic organoids in 3D culture. (Right) PLAs performed on bone
N-cad (membrane) and Osterix (nuclear). (Bottom Left) PLA using N-cad and
ining on bone lesions shows the presence of a metastasis. (Bottom Right) PLA
ell cores and microscopic lesions.
F-7 lesions are unlabeled but indicated by the dashed line. Signalsmerged from
or CTSK (bottom).
l Erasmus (EMC) data set (GSE5327, GSE2034, and GSE12276) in relationship
tients in each group are indicated. The p value was calculated by log rank test.
east cancer metastases at different anatomical sites. Gray dots superimposed
eses. The p values are between bone metastases and all other metastases
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Figure 5. Disruption of the hAJs Abolishes the Promoting Effects of the Osteogenic Niche
(A) Quantification of firefly luciferase-labeled MCF-7 cells cultured with or without equal amount of MSCs in 3D cultures under treatments of 1 mM EGTA. EGTA
treatment started on day 0. BL signals were measured on day 3 and normalized to untreated MCF-7 cells without MSCs (n = 3–5). The p values between treated
and untreated conditions are indicated; n.s., not significant.
(B–E) Quantification of firefly luciferase-labeled MCF-7 cells with or without coculture of equal amount of MSCs under different treatments with neutralizing
antibody against E-cad (anti-Ecad) (B), doxycycline (Dox) to induce the expression of DN-Ecad in cancer cells (C), neutralizing antibody against N-cad (anti-Ncad)
(D), or siRNAs against N-cad inMSCs (si-Ncad) (E). BL signals weremeasured on day 5 to allow the treatments to take effects, and normalized to untreatedMCF-7
cells without MSCs (n = 3–5). For (C), the ratio between +MSC and –MSC conditions (+/MSC) was calculated for each condition and is shown in the dotted line
box, and a p valuewas calculated and is shown for the ratios. Pictures to the right of the bar graphs show the representative fluorescent imaging of the heterotypic
organoids formed by GFP-labeled MCF-7 cells and unlabeled MSCs with or without the corresponding treatment.
(F) Quantification of MCF-7 cells growing in plates coated with the indicated recombinant proteins (n = 5).
(legend continued on next page)
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inducible expression did not suppress orthotopic tumor growth
(Figure S5E). Taken together, these results provide support for
an important role of AJs in early-stage bone colonization.
Interaction between Osteogenic Cells and Cancer Cells
Activates the mTOR Pathway in Cancer Cells
We performed a phospho-antibody array on the heterotypic
organoids formed by MCF-7 cells and MSCs. Spheres of
MCF-7 cells alone, MSCs alone, and their admixture were
used as controls to delineate molecular reactions selectively eli-
cited by direct MSC-cancer contact (Figure 6A). Among the total
of 39 phosphoproteins, the phosphorylation on Ser235/236 of
ribosomal protein S6 (pS6RP[S235/S236]) displayed a marked
increase in the heterotypic organoids (Figure 6A). S6RP is a
substrate of S6 kinase (S6K), which is in turn a direct substrate
of themTOR kinase. Amore quantitative analysis of low-intensity
signals of other phosphoproteins on the array revealed a 1.7- to
1.8-fold increase of pAKT(Ser473) and pAKT(T308) (Figure S6A).
To validate the activation of the AKT-mTOR pathway in the het-
erotypic organoids, we performed western blots to examine the
phosphorylation status of AKT, S6K, and 4EBP1. Like S6, S6K
and AKT were significantly activated (Figure 6B). We asked if
the enhancement of mTOR activity occurs in cancer cells.
MSCs exhibited a constitutively high level of p4EBP1(T37/T46),
masking any alterations in cancer cells (Figure 6B). However,
the S6K activity was exclusively restricted to the cancer cells
in the heterotypic organoids (Figure 6C). A similar observation
also was made using MC3T3 cells (Figure S6B). Taken together,
these results indicate that the direct contact between cancer and
osteogenic cells activates the mTOR pathway in cancer cells.
The Enhancement of mTOR Activity Requires hAJs
In Vitro and In Vivo
EGTA abolished the osteogenic cell-induced increase of mTOR
activity in cancer cells, and the abolishment was rescued by
Ca2+ (Figures 6D and S6C). Similarly, induction of DN-Ecad
also led to a reduction of pS6K(T389) (Figure 6E). N-cad deple-
tion in osteogenic cells decreased their effects on the mTOR
activity in cancer cells (Figure 6F). Finally, N-cad-coated plates
stimulated the mTOR activity in cancer cells to a greater degree
than E-cad and OB-cad (Figure 6G). These data strongly support
that hAJs promote cancer cell proliferation via enhancing the
activity of the mTOR pathway in cancer cells.
To validate the cellular source of the mTOR activity in hetero-
typic organoids, we examined the in situ IF staining of
pS6K(T389) when E-cad in cancer cells was blocked by anti-
Ecad (Figure 6H) or by the expression of DN-Ecad (Figure 6I),
or when N-cad in osteogenic cells was antagonized by anti-(G) Representative BL images of mice that were subjected to IIA injection of 5 3
control IgG are shown. The images at the bottom show extracted bones examin
(H) (Left) BL intensity (normalized to day 0 values) as a function of time after IIA inje
for IgG and anti-Ecad, respectively). Error bars, 95% CI. The p value was determi
show ex vivo BL signal intensity of hind limb bones from the same experiment d
(I) IF staining of Ki67 and cancer cells in microscopic bone lesions (GFP-tagged M
green, GFP).
(J–L) The same as (G–I), respectively, except that doxycycline induction of DN-Eca
95% CI.
Error bars, SD except (H) and (K). Scale bar, 25 mm. See also Figure S5.
CNcad (Figure 6J) or by si-Ncad (Figure 6K). Under these condi-
tions, pS6K(T389) signals remained exclusively to cancer cells
and exhibited a significant decrease in intensity.
In vivo, IF staining of pS6K(T389) revealed robust mTOR
signaling in multicell lesions (Figure S6D, red arrows). Very
weak or no pS6K(T389) staining was detected in cancer cells
that remain solitary or in loose clusters in the same field (Fig-
ure S6D, white arrow), suggesting that the activation of mTOR
accompanies bone metastasis progression from single cells to
microscopic lesions. Both anti-Ecad or DN-Ecad treatment re-
sulted in a lower pS6K(T389) level (Figures 6L and 6M) in the
bone lesions, suggesting that the enhanced mTOR activity in
cancer cells is dependent on their interaction with osteogenic
cells via hAJs both in vitro and in vivo.
Inhibition of the mTOR Pathway Reversed the
Osteogenic Cell-Conferred Growth Advantage
We transduced MCF-7 cells with shRNAs against Raptor or
Rictor, the necessary components of mTOR Complexes 1 and
2, respectively (Figure S7A). The depletion of these proteins in
cancer cells partially abolished the osteogenic cell-conferred
growth advantage in 3D cocultures (Figure S7B). Furthermore,
MCF-7 cells with Raptor or Rictor knockdown exhibited signifi-
cantly decreased bone colonization in the preosteolytic stage
(Figure 7A). In contrast, the orthotopic tumor growth was only
modestly affected by the same shRNAs during the same time-
frame (Figure S7C). Depletion of Raptor or Rictor in osteogenic
cells did not affect their ability to promote cancer cell prolifera-
tion (Figure S7D). We then used mTOR inhibitors to achieve a
more complete, pharmacological blockade of this pathway.
Two inhibitors, Torin 1 (Thoreen et al., 2009) and rapamycin,
without affecting the proliferation or survival of osteogenic cells
(Figure S7E), potently reduced the osteogenic cell-conferred
gowth advantage on cancer cells (Figures S7F and S7G). In
contrast, the MEK inhibitor, PD98085, failed to achieve the
same effect (Figure S7F), arguing against a role of the MAPK
pathway in this process. Torin 1 also abolished the N-cad-
induced proliferation (Figure S7H), suggesting that mTOR medi-
ates the downstream signaling of E-N hAJs.
In vivo treatment with Torin 1 or rapamycin significantly de-
layed bone colonization of MCF-7 cells (Figure 7B). Torin 1 treat-
ment of 4TO7 bone lesions in BALB/c mice resulted in a similar
effect (Figure 7C). Solitary disseminated cancer cells were
largely Ki67-negative and cleaved caspase-3-negative in both
treated and control groups, suggesting that these cells are
quiescent and do not respond to Torin 1 (Figure 7D, white
arrows). This is consistent with the fact that solitary cancer cells
in the bone marrow in general possess low mTOR activity105 MCF-7 cells and treated with E-cad neutralizing antibody (anti-Ecad) or
ed after resection. W0–W3, weeks 0 to 3 after IIA injection.
ction of 53 105 MCF-7 cells with or without treatment of anti-Ecad (n = 5 and 8
ned by fitting a generalized linear model as implemented by R. (Right) Dot plots
escribed in (G).
CF-7 cells) with or without the treatment of anti-Ecad (blue, DAPI; purple, Ki67;
d was used to treat mice instead of anti-Ecad (n = 5 for each group). Error bars,
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(Figures S6D and S7I). Multi-cell lesions, on the other hand, ex-
hibited decreased proliferationwith Torin 1 treatment (Figure 7D),
but the survival/apoptosis appeared unaffected. Interestingly, at
later stages of bone colonization, although the mTOR activity re-
mained high (Figure S7I), Torin 1 treatment no longer delayed
bone colonization (Figures 7D and S7J). These results suggest
that the bone colonization process may be dependent on the
enhanced mTOR activity, specifically at the early stage when
cancer cells are associated with the osteogenic niche. In later
stages, although the mTOR activity might still be on, it may not
be essential for the further progression of bone metastases.
The Increase of mTOR Activity Is Associated with Bone
Metastasis Progression from DTCs in Human Breast
Cancer
We interrogated themTOR activity in a previously published data
set comprised of transcription profiles of human DTCs and overt
bonemetastases (Cawthorn et al., 2009). ThemTOR activity was
inferred using two signatures derived by profiling transcriptional
responses of various cell line models to rapamycin (Wei et al.,
2006) and PP242 treatment (Wang et al., 2011). Like Torin 1,
PP242 is a newly developed mTOR inhibitor targeting both
mTORC1 and mTORC2 (Hsieh et al., 2010). We first applied
these signatures to the Cancer Genome Atlas database microar-
rays with matched reverse-phase protein array (RPPA) data
(Cancer Genome Atlas Network, 2012), and confirmed their cor-
relation with upstream regulators and downstream substrates of
the mTOR pathway (Figure 7E). Using these signatures, we
found that the predicted mTOR activity is significantly higher in
bone metastases compared to in DTCs (Figure 7F), supporting
that enhancement of mTOR activity is associated with bone
metastasis progression.
The Osteogenic Niche of Spontaneous Bone
Micrometastases
To validate our findings in spontaneous metastasis models, we
used the 4T1.2 cell line, which was shown to give rise to sponta-
neous metastasis to bone and other organs (Figure S8A; Eck-
hardt et al., 2005). In addition, we identified one tumor line
derived from p53 null BALB/c mice (Herschkowitz et al., 2012),
termed 2208L, which spontaneously metastasizes to bone and
bone marrow as indicated by tumor-specific PCR (Figure S8B).Figure 6. The hAJs between Cancer Cells and the Osteogenic Niche A
(A) Phospho-antibody arrays hybridized with protein lysates of MCF-7 mammo
spheres, and heterotypic organoids.
(B) Western blots show the expression level of indicated proteins and phosphop
of MSCs.
(C) IF staining of RFP (red) and pS6K(T389) (green) in the heterotypic organoids
channels (blue, DAPI). (Right) Signals from green channel only.
(D)Western blots show the level of indicated proteins and phosphoproteins inMC
of MSCs. The protein lysates were prepared 4 hr after the cultures began. MCF-7
cancer cell quantities. Torin 1 is an mTOR inhibitor.
(E) Western blots show the impact of doxycycline (Dox)-induced expression of D
(F) Western blots show the impact of the expression of siRNA against N-cad in M
(G) Western blot shows the effects of coated cadherin proteins on pS6K(T389) a
(H–K) IF staining of GFP and pS6K(T389) of heterotypic organoids formed betwee
expression of DN-Ecad in cancer cells (I), anti-Ncad (J), or expression of siRNA
(L and M) IF staining of GFP-labeled MCF-7 cells (green) and pS6K(T389) (red)
DN-Ecad (M); blue, DAPI; green, GFP; red, pS6K(T389).
Scale bar, 25 mm. See also Figure S6.
CBoth 4T1.2 and 2208L express E-cad (Figure S8C). We exam-
ined hind limb bones 2 weeks or 1 month after resection of
orthotopic 4T1.2 or 2208L tumors, respectively (Figure 8A). All
microscopic multicell lesions we could observe in the bone
(n = 3) directly contacted ALP+ and Col-I+ cells, but not CTSK+
cells (Figures 8B and S8D). Further experiments revealed
that 4T1.2 spontaneous bone metastases exhibited positive
pS6K(T389) staining (Figure 8C) and expressed E-cad that was
colocalized with the N-cad of the niche (Figure 8D). We next
investigated the effects of anti-Ecad and Torin 1 treatment on
spontaneous bone metastases. Orthotopic 4T1.2 tumors were
resected prior to the treatment with anti-Ecad (Figure 8E) or
Torin 1 (Figure 8F). While anti-Ecad and Torin 1 significantly
decreased bonemetastases, they had little effect on lungmetas-
tasis (Figures 8E and 8F) or residual orthotopic tumors (Fig-
ure S8E), suggesting bone specificity. Similar effects of Torin 1
treatment on 2208L bone lesions were observed using a
qPCR-based approach. (Figure S8F). Taken together, these
results strongly support the conclusion that hAJs and mTOR
signaling drives early-stage bone colonization in both IIA and
spontaneous models.
DISCUSSION
We have characterized the microenvironment niche of bone
microscopic lesions, which is primarily comprised of cells in
the osteoblast lineage and possess osteogenic potential (Fig-
ure 8G). Our data showed that a substantial proportion of the
osteogenic cells still express Osterix and RUNX2, markers of
osteo-progenitor cells, suggesting an ongoing osteogenesis
process. Thus, the microenvironment niche of bone micrometa-
stases is dynamic. An important question is regarding the rela-
tionship between the osteogenic niche observed here with the
long-proposed endosteal osteoblastic niche harboring hemato-
poietic stem cells (HSCs) (Calvi et al., 2003). A previous study
showed IC injection of prostate cancer cells increased HSC fre-
quency in the blood, suggesting that cancer cells may compete
against HSC for niches as the first foothold of bone colonization
(Shiozawa et al., 2011). Our data cannot directly test this hypoth-
esis as the exact constitution and organization of the HSC niche
remain largely uncertain. The answers to these questions need to
be addressed in future studies.ctivate the mTOR Pathway in Cancer Cells
spheres, MSC-spheres, admixture of preformed mammospheres and MSC-
roteins in the cell lysates after 4 hr coculturing with or without equal amount
of RFP-labeled MSCs and unlabeled MCF-7 cells. (Left) Signals from all three
F-7 mammospheres or heterotypic organoids of MCF-7 cells and equal number
cells were tagged with firefly luciferase (Fluc), which was used as the control of
N-Ecad on pS6K(T389).
SCs on pS6K(T389).
nd p4EBP (T37/T46) in MCF-7 cells.
n MCF-7 cells and MSCs with or without treatment of anti-Ecad (H), inducible
against N-cad in MSCs (K); blue, DAPI; green, GFP; red, pS6K(T389).
of microscopic lesions in bones with or without treatment of anti-Ecad (L) or
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Our data indicate an important role of AJs in early-stage bone
colonization. When E-cad-positive cancer cells disseminate to
the bone and bone marrow as single cells, the first AJs they
are able to form are likely to be E-N hAJs, because of the scarcity
of E-cad and the abundance of N-cad in the microenvironment
(Figure 8G). Thus, the formation of E-N hAJs may represent the
first critical step of bone colonization. After the first few cell divi-
sions, E-E homotypic junctions form between daughter cancer
cells, which may contribute to fueling further progression,
although, according to our data, E-N heterotypic AJs may still
confer a stronger proliferative advantage. Other cadherins ex-
pressed in cancer cells also may be involved in heterotypic
AJs. In fact, 4TO7 only expressed a minimal level of E-cad (Fig-
ure S4A), which is consistent with previous studies (Korpal et al.,
2011). Correspondingly, the effects of E-cad neutralization were
modest in 4TO7 coculture assays (Figure S5A), despite the
similar dependency of these cells on osteogenic cell-derived
N-cad (Figure S5B) and the mTOR pathway (Figure S7F). Thus,
we cannot rule out the possibility that other cadherins contribute
to the formation of hAJs with N-cad.
We found that the enhancement of the mTOR pathway is a
consequence of E-N hAJs. The mTOR signaling has been impli-
cated in resistance to endocrine therapies in ER+ breast cancer
(Boulay et al., 2005; Schiff et al., 2004). A recent Phase III clin-
ical trial on postmenopausal endocrine-resistant breast cancer
revealed an increase in progression-free survival when Everoli-
mus, a rapamycin analog, was used in combination with an
aromatase inhibitor Exemestane (Baselga et al., 2012). Of the
patients in this trial, 76% had bone metastases, indicating
that the mTOR inhibitor may efficiently inhibit the progression
of metastatic colonization in bone. However, another Phase III
trial using a different combination of rapalog and aromatase in-
hibitor as the first-line therapy failed to achieve the same effi-
cacy (Wolff et al., 2013). Thus, additional studies are required
to understand how different mTOR inhibitors act on breast can-
cer of various subtypes, in distinct stages, at different sites, and
with diverse treatment history. Our findings and experimental
models should help facilitate the understanding of how mTOR
functions to promote progression from single DTCs to micro-
scopic bone metastases.Figure 7. The mTOR Pathway Mediates the Initiation of Bone Coloniza
(A) (Left) Representative BL pictures of mice receiving IIA injection of 5 3 105 MC
vectors (GIPZ). (Middle) BL signal intensity (normalized to day 0 values) as a funct
Raptor (shRa) or Rictor (shRi), or vehicle control (n = 10 for each group). Mice with c
this plot (shRa-1/2 or shRi1/2). The statistical significance was assessed by fitti
Quantification of BL signal intensity of bone lesions at the terminal time point (w
distinguished by color. Error bars, SD.
(B) (Left) Representative BL pictures of mice that were subjected to IIA injection o
signal intensity (normalized to day 0 values) as a function of time after IIA injection
control (n = 8–9 for each group). The statistical significance was assessed by fittin
plots show BL signal intensity of bone lesions at the terminal time point (week 4)
(C) Same as (B) except that 5 3 103 4TO7 cells were used instead of MCF-7 cel
(D) (Left) Cleaved caspase-3 (CC3, red) and Ki67 (red) staining of bonemetastases
Arrows indicate solitary cancer cells. Scale, 25 mm. (Right) Quantification of Ki67
Torin 1 is shown (n = 5; error bars, SD). C, control; T, Torin 1 treatment; early, da
(E) Validation of the rapamycin-responsive signature (Rapa-Sig) and PP242-respo
scores were calculated as specified in Experimental Procedures. Pearson corre
phoproteins in RPPA. The p values were determined based on Student’s t tests
(F) PP242-Sig and Rapa-Sig were applied to GSE14776. The scores were tabula
See also Figure S7.
CEXPERIMENTAL PROCEDURES
Animal Studies
All animal work was done in accordance with a protocol approved by the
Baylor College of Medicine Institutional Animal Care and Use Committee.
IIA Injection
Anesthetized mice were restrained on a plastic board. A 1.5 cm incision was
made on the skin along the line between femoral and ilium bones. Blunt dissec-
tion was performed to separate muscles and reveal the common iliac artery.
Cancer cells suspended in 0.1 ml PBS were injected using 31G needles. A
cotton tip was used to press injected artery until the bleeding stopped (in about
10 min). The wound was then sutured, and the mouse was monitored until
awake and moving normally.
Spontaneous Bone Metastasis Assay
BALB/c mice received mammary fat pad transplantation of 1–2 mm fragments
of 2208L tumors or 53 105 4T1.2 cells suspended in 100 ml PBS. When tumors
reached1 cm3, surgical resectionwas used to remove the tumors.Micewere
excluded from experiments if their tumor size was exceptionally large or small
(2 SD from the group mean), or if the residual tumor signals were exceptionally
strong after resection. The remaining mice were randomized into different
treatment groups and closely monitored for 1 month (2208L) or 2 weeks
(4T1.2) before being sacrificed. Immediately after euthanasia, hind limb bones
(for 2208L and 4T1.2 models), spines (4T1.2), and lungs (4T1.2) were extracted
for further analyses. In 2208L experiments, genomic DNA was purified from
homogenized tissue. Quantitative PCR was then conducted using the primer
sequences: 50-CTCTGATGCCGCCGTGTT-30 and 50- TGCCTCGTCTTGCA
GTTCATT-30 to specifically detect cells with the p53-KO locus. The actin
gene was used as the control. The relative quantity was calculated using the
formula log2(10,000/DCt) (Eckhardt et al., 2005). The Student’s t test was
used to compute the p value.
See the rest of the animal study procedures in Supplemental Experimental
Procedures.
Quantification of Cells in the Microenvironment Niche
Toluidine blue and TRAP staining were performed, and montaged images of
the femur were taken and analyzed in the BCM bone Histomorphometry
Core following standard procedures. We defined the microenvironment niche
as the collection of stromal cells immediately adjacent to and directly contact-
ing cancer cells, where there was neither discernible space between the
plasma membranes of the two cells nor additional nucleus between the nuclei
of the two cells.
Statistical Tests
Differences among growth curves were assessed using generalized linear
models in the statmod package of the R statistical software. Values at growth
curve time points were first converted to log scale to approximate the normaltion
F-7 cells expressing shRNAs against Raptor (shRa) or Rictor (shRi) or control
ion of time after IIA injection of 53 105 MCF-7 cells expressing shRNAs against
ancer cells expressing shRNAs against the same gene were pooled together in
ng a generalized linear model as implemented by R. Error bars, SEM. (Right)
eek 4). Different shRNAs against the same gene (shRa-1/2 or shRi1/2) were
f 53 105 MCF-7 cells and treated with indicated drugs are shown. (Middle) BL
of 53 105 MCF-7 cells under the treatment of Torin 1, rapamycin, and vehicle
g a generalized linear model as implemented by R. Error bars, SEM. (Right) Dot
in the same experiment. Error bars, SD.
ls. Error bars, SD.
at different time points is shown. Cancer cells are stainedwith Keratin 8 (green).
-positive cells in bone lesions at different stages with or without treatment of
y 21 after injection; late, day 42 after injection.
nsive signature (PP242-Sig) in the Cancer GenomeAtlas data set. The signature
lation coefficients were computed between the scores and the level of phos-
and are shown in parentheses below the correlation coefficients.
ted by the sample type (DTC versus overt bone metastases). Error bars, SD.
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distribution, and then used to derive the SD or 95% confidence interval of the
mean using standard procedures. For other analyses, Student’s t tests were
used unless noted otherwise.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and eight figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccell.2014.11.017.
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